A partnership with a bigger pharma company with a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales. I honestly could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them.
People need to ask why the co-founder of Amgen is wasting his time here. Why is he presenting along with the CSO at a biotech conference known for bringing investments to biotech startups? Why did he state that MANF could be the biggest success he has ever seen in his career?
And why did Hermo Pharma challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to college kids on this board with their $3,000 in life savings trying to bash a stock. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have more knowledge.
News 
Market Data 
Discover 
AI
